Business
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family OfficeKing of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene...
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event","length":119,"tagName":"p"},{"type":"text","content":"R. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family Office","length":156,"tagName":"p"},{"type":"text","content":"King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. R. Todd Plott, Chief Medical Officer, Epiphany Dermatology and former consultant to the FDA who will provide additional insight on PH-762, an INTASYL compound, that silences the PD-1 gene implicated in various forms of skin cancer.","length":705,"tagName":"p"},{"type":"text","content":""We are excited to hold this fireside chat with Force Family Office. Dr. Plott will discuss why the INTASYL siRNA program represents a differentiated approach to immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.","length":254,"tagName":"p"},{"type":"text","content":"DATE: Wednesday April 15, 2026","length":30,"tagName":"p"},{"type":"text","content":"TIME: 12 PM EDT","length":15,"tagName":"p"},{"type":"text","content":"REGISTRATION LINK: PHIO Pharma - Force Family Office","length":52,"tagName":"p"},{"type":"text","content":"Recent Company HighlightsPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.","length":571,"tagName":"p"},{"type":"text","content":"Phio has indicated that ...